Ocular Photodynamic Therapy (OPT) with Verteporfin for Macular Degeneration
Guidance for the expansion of coverage of OPT with verteporfin for “wet” AMD. CMS is revising the requirements for testing to permit either optical coherence tomography (OCT) or FA to assess treatment response.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: June 14, 2013
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.